Trial Profile

Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Huperzine A (Primary)
Indications Seizures
Focus Proof of concept; Therapeutic Use
Acronyms FIAS
Sponsors Biscayne Neurotherapeutics; Supernus Pharmaceuticals

Most Recent Events

26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
13 Apr 2021 Planned End Date changed from 30 Nov 2018 to 30 Dec 2026.
13 Apr 2021 Planned primary completion date changed from 30 Nov 2018 to 30 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com